SOS PMDD

(Symptom Onset Study for Premenstrual Dysphoric Disorder)

New York City, New Haven, CT and Richmond, VA

PMDD or severe PMS affects 5-8% of women, causing significant disruption of their lives at home and at work. Relationships and productivity can be severely impaired.

Currently two treatment methods have been approved by the Food and Drug Administration (FDA) for treatment of PMDD:

• three serotonin reuptake inhibiting antidepressants (SSRIs)
• an oral contraceptive containing the progestin drosperinone.
  

Researchers at three universities are now working together to test a new method of using SSRIs only on symptomatic days, in an attempt to reduce the side effects and cost of SSRI treament. This study is funded by the National Institute of Mental Health.  Participants receive a free comprehensive evaluation of their symptoms during the screening phase and are reimbursed for their time.  To learn more about the study click the "About the Research Study" bar on the right.

To learn more about PMDD click the "Information About PMDD" bar on the right.  If you would like to be notified when new information about PMDD is added to the website click the orange "Journal RSS" button on the right.